Effect of Sex and Age on HbA1c, Body Weight, and Systolic Blood Pressure Reduction with Dapagliflozin

被引：0
|
作者：
Reusch, Jane E. B.
Day, Danielle
Wortzman-Show, Genevieve
Katz, Arie
Regensteiner, Judith G.
机构：
来源：
DIABETES | 2015年 / 64卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1253-P
引用
收藏
页码：A325 / A325
页数：1
相关论文
共 50 条
  • [1] HbA1c, weight, body mass index (BMI) and systolic blood pressure changes in the ABCD nationwide dapagliflozin audit
    Yadagiri, M.
    Sen Gupta, P.
    Cull, M. L.
    Eyles, J.
    Robinson, A.
    Oguntolu, L.
    Imtiaz, K.
    Adamson, K.
    Ryder, R. E. J.
    DIABETIC MEDICINE, 2016, 33 : 164 - 164
  • [2] HbA1c, Weight, Body Mass Index (BMI), and Systolic Blood Pressure Response to Dapagliflozin: The Association of British Clinical Diabetologists Nationwide Dapagliflozin Audit
    Yadagiri, Mahender
    Sen Gupta, Piya
    Kennedy, Adele
    Pang, Terence
    Clark, James
    Pathan, Hafsa
    Johnston, Phillip C.
    Chudleigh, Richard
    Robinson, Anthony
    Gallen, Ian W.
    Adamson, Karen A.
    Ryder, Robert E. J.
    DIABETES, 2016, 65 : A305 - A306
  • [3] Achievement of HbA1c Goal and Body Weight and Systolic Blood Pressure Reduction When Treated with Dapagliflozin in Patients with Type 2 Diabetes Stratified by Disease Duration
    Yeh, Helen
    Katz, Arie
    Moran, Jason
    DIABETES, 2015, 64 : A313 - A313
  • [4] Achieving the composite endpoint of HbA1c, body weight, and systolic blood pressure reduction with canagliflozin in patients with type 2 diabetes
    Merton, Katherine
    Davies, Michael J.
    Vijapurkar, Ujjwala
    Inman, Doreen
    Meininger, Gary
    CURRENT MEDICAL RESEARCH AND OPINION, 2018, 34 (02) : 313 - 318
  • [5] Reductions in HbA1c and Systolic Blood Pressure in Patients with Type 2 Diabetes Treated with Dapagliflozin
    Moran, Jason
    Katz, Arie
    Yeh, Helen
    DIABETES, 2015, 64 : A309 - A309
  • [6] Achieving composite endpoint of HbA1c, body weight, and systolic blood pressure reduction with canagliflozin in patients with type 2 diabetes
    Merton, K.
    Davies, M. J.
    Vijapurkar, U.
    Inman, D.
    Meininger, G.
    DIABETOLOGIA, 2016, 59 : S345 - S345
  • [7] Changes in HbA1c, body weight, and systolic blood pressure in type 2 diabetes patients initiating dapagliflozin therapy: a primary care database study
    Scheerer, Markus F.
    Rist, Roland
    Proske, Orm
    Meng, Annika
    Kostev, Karel
    DIABETES METABOLIC SYNDROME AND OBESITY-TARGETS AND THERAPY, 2016, 9 : 337 - 345
  • [8] Changes in HbA1c, body weight, and systolic blood pressure in type 2 diabetes patients initiating dapagliflozin therapy: a German primary care database study
    Scheerer, M. F.
    Rist, R.
    Proske, O.
    Meng, A.
    Kostev, K.
    DIABETOLOGIA, 2016, 59 : S337 - S338
  • [9] Combined HbA1c and Systolic Blood Pressure Reduction With Dapagliflozin in Patients With Both Inadequately Controlled Type 2 Diabetes Mellitus and Hypertension
    Weber, Michael A.
    List, James
    Mansfield, Traci A.
    Parikh, Shamik J.
    Ptaszynska, Agata
    CIRCULATION, 2014, 130
  • [10] Clinical Response (HbA1c ≥1% and/or Body Weight ≥5% Reduction) to Semaglutide by Baseline HbA1c and Body Weight in the SUSTAIN Program
    Aroda, Vanita R.
    Larsen, Julie F.
    Ostoft, Signe Harring
    Rea, Rosangela R.
    Sugimoto, Danny
    Ziegler, Uwe
    Vilsboll, Tina
    DIABETES, 2019, 68
12345